ReviewThe Journal of biological chemistry2010
Daptomycin, a bacterial lipopeptide synthesized by a nonribosomal machinery.
Review in The Journal of biological chemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 201 citations in OpenAlex.
- Exploring RiPP-derivedRSC chemical biology · 2026Article
- Linking molecular architecture to antibacterial functions: a chemical biology view of cyclic depsipeptides.Frontiers in chemistry · 2026Review
- In-Situ Purification of Non-Ribosomal Peptide Synthetases Assembly Line for Structural and Biochemical Studies.International journal of molecular sciences · 2025Article
- Antimicrobial Peptides: Mechanisms, Applications, and Therapeutic Potential.Infection and drug resistance · 2025Review
- Chemoenzymatic Modification of Daptomycin: Aromatic Group Installation on Trp1.Chembiochem : a European journal of chemical biology · 2024Article
- Metabolic engineering of Streptomyces roseosporus for increased production of clinically important antibiotic daptomycin.Microbial biotechnology · 2024Article
- Non-modular fatty acid synthases yield distinct N-terminal acylation in ribosomal peptides.Nature chemistry · 2024Article
- Development of a group II intron-based genetic manipulation tool for Streptomyces.Microbial biotechnology · 2024Article
- Chemoenzymatic synthesis of macrocyclic peptides and polyketides via thioesterase-catalyzed macrocyclization.Beilstein journal of organic chemistry · 2024Review
- Daunorubicin resensitizes Gram-negative superbugs to the last-line antibiotics and prevents the transmission of antibiotic resistance.iScience · 2023Article
- A Comprehensive Review on the Biological, Agricultural and Pharmaceutical Properties of Secondary Metabolites Based-Plant Origin.International journal of molecular sciences · 2023Review
- Actinobacteria from Arctic and Atlantic deep-sea sediments-Biodiversity and bioactive potential.Frontiers in microbiology · 2023Article
- m4C DNA methylation regulates biosynthesis of daptomycin inSynthetic and systems biotechnology · 2022Article
- Transcriptional Regulator DasR Represses Daptomycin Production through Both Direct and Cascade Mechanisms inAntibiotics (Basel, Switzerland) · 2022Article
- AvmM catalyses macrocyclization through dehydration/Michael-type addition in alchivemycin A biosynthesis.Nature communications · 2022Article
- Lights and Shadows on the Therapeutic Use of Antimicrobial Peptides.Molecules (Basel, Switzerland) · 2022Review
- A novel strategy of gene screen based on multi-omics in Streptomyces roseosporus.Applied microbiology and biotechnology · 2022Article
- Ribosomally derived lipopeptides containing distinct fatty acyl moieties.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Comparative Genomics Reveals Insights into Induction of Violacein Biosynthesis and Adaptive Evolution inMicrobiology spectrum · 2021Article
- New Perspectives on Old and New Therapies of Staphylococcal Skin Infections: The Role of Biofilm Targeting in Wound Healing.Antibiotics (Basel, Switzerland) · 2021Review
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Daptomycin (Cubicin) is a branched cyclic lipopeptide antibiotic of nonribosomal origin and the prototype of the acidic lipopeptide family. It was approved in 2003 for the nontopical treatment of skin structure infections caused by gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), and in 2006 for the treatment of bacteremia. Understanding the ribosome-independent biosynthesis of daptomycin assembly will provide opportunities for the generation of daptomycin derivatives with an altered pharmaceutical spectrum to address upcoming daptomycin-resistant pathogens. Herein, the structural properties of daptomycin, its biosynthesis, recent efforts for the generation of structural diversity, and its proposed mode of action are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.